Date: Jun 06, 2013 Author: Chad Swiatecki Source: bizjournals (
click here to go to the source)
Luminex Corp. (Nasdaq: LMNX) has renewed its agreement with German researcher Merck KGaA (Nasdaq: MKGAY) to distribute its selection of xMap systems, including MAGPIX, Luminex 100/200 and FLEXMAP 3D through Merck's life science division, EMD Millipore.
Luminex's technology is widely supported and validated across clinical and life science research markets, with cumulative shipments to date nearing 10,000 total instruments and more 16,000 publications across a broad spectrum of applications.
Luminex, which was founded in 1995, develops testing equipment to identify conditions such as illnesses in humans or biological weapons. The company employs about 614 workers.
The company reported a first-quarter loss of $2.5 million on revenue of $53.2 million
